{
    "clinical_study": {
        "@rank": "72295", 
        "acronym": "EVOLVE", 
        "arm_group": {
            "arm_group_label": "ColoAd1", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multicentre, open-label, Phase I/II study of ColoAd1 in patients with either solid\n      tumour of epithelial origin not responding to standard therapy or for whom no standard\n      treatment exists (phase I Dose Escalation) or metastatic colorectal cancer not responding to\n      standard therapy (Phase I dose Expansion) or metastatic colorectal cancer in stable disease\n      or partial response after 3-4 months of first line standard of care chemotherapy (phase II).\n\n      The dose of ColoAd1 will be administered intravenously once daily as 3 consecutive\n      injections separated by 48 hours (hrs.) over a period of five days unless an unacceptable\n      toxicity occurs."
        }, 
        "brief_title": "Phase I / II Study of ColoAd1 by Sub-acute Fractionated IV Dosing in Cancer Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumours of Epithelial Origin", 
            "Metastatic Colorectal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must provide written informed consent\n\n          -  Age \u2265 18 years and the patient must be at least the legal age limit to be able to\n             give consent within the jurisdiction the study is taking place.\n\n          -  ECOG performance status 0 or 1 (See Appendix 1) * Predicted life expectancy of 3\n             months or more\n\n          -  Ability to comply with study procedures in the Investigator's opinion\n\n          -  Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for\n             their malignancies.\n\n          -  Adequate renal function:\n\n               -  Creatinine \u2264 1.5 mg/dL or calculated creatinine clearance using the\n                  Cockcroft-Gault formula \u2265 60 mL/min, or measured creatinine clearance \u2265 60\n                  mL/min,\n\n               -  Absence of clinically  significant haematuria or proteinuria on urinalysis\n                  defined as follows:\n\n                    -  Haematuria: dipstick < 2+\n\n                    -  Proteinuria: dipstick < 2+.\n\n          -  Adequate hepatic function:\n\n               -  serum bilirubin < 1.5 mg/dL\n\n               -  AST and ALT \u2264 3 x ULN\n\n          -  Adequate bone marrow function:\n\n               -  ANC \u2265  1.5 x 109/L,\n\n               -  platelets \u2265 100 x 109/L,\n\n               -  haemoglobin \u2265 90 g/L\n\n          -  Adequate coagulation tests: INR \u2264 1.5 x ULN;\n\n          -  For females of childbearing potential (defined as <2 years after last menstruation or\n             not surgically sterile), a negative serum pregnancy test must be documented within 14\n             days prior to first administration of study treatment; -- For women who are not\n             postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries\n             and/or uterus):  agreement to use two adequate methods of contraception, during the\n             treatment period and for at least 3 months after the last dose of study drug;\n\n          -  For men: agreement to use a barrier method of contraception during the treatment\n             period and for at least 6 months after the last dose of study drug;\n\n          -  At least 3 weeks since any dose of intravenous systemic chemotherapy and at least two\n             weeks since any oral dose of capecitabine at the time of first administration of\n             ColoAd1.\n\n          -  Phase I specific inclusion criteria Dose-escalation stage only (except Repeat cycle\n             cohort):\n\n               -  Solid tumour of epithelial origin not responding to standard therapy or for whom\n                  no standard treatment exists  Dose Expansion Stage and Dose-escalation Stage\n                  Repeat cycle cohort\n\n               -  Metastatic colorectal carcinoma not responding to standard therapy\n\n               -  \u2264 3 prior lines of systemic therapy for advanced disease OR \u2264 4 prior lines of\n                  systemic therapy for advanced disease if one of the 4 lines was an anti-EGFR\n                  therapy given as a single agent or combined to a previously administered\n                  chemotherapy regimen;\n\n          -  Phase II specific inclusion criteria:\n\n               -  Metastatic colorectal cancer;\n\n               -  Have received 3 - 4 months of first line chemotherapy with either FOLFOX,\n                  FOLFIRI or CAPOX, with or without bevacizumab;\n\n               -  At least one measurable lesion according to RECIST 1.1 criteria ; * Documented\n                  partial response or stable disease;\n\n               -  Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy\n                  interruption (3 to 4 weeks).\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast feeding females;\n\n          -  Known history or evidence of significant immunodeficiency due to underlying illness\n             (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids, or other\n             immunosuppressive medications including cyclosporine, azathioprine, interferons,\n             within the past 4 weeks);\n\n          -  Splenectomy;\n\n          -  Prior allogeneic or autologous bone marrow or organ transplantation;\n\n          -  Active infections requiring antibiotics, physician monitoring, or recurrent fevers\n             >38.0 degrees centigrade associated with a clinical diagnosis of active infection ;\n\n          -  Active viral disease or known positive serology for HIV, hepatitis B or hepatitis C;\n\n          -  Use of the following anti-viral agents: ribavirin, adefovir, lamivudine or cidofovir\n             within 7 days prior to day 1; or PEG-IFN (within 14 days prior to first\n             administration of ColoAd1);\n\n          -  Administration of an investigational drug within 28 days prior to first dose of\n             ColoAd1;\n\n          -  Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of\n             ColoAd1;\n\n          -  Another primary malignancy within the past 3 years (except for non-melanoma skin\n             cancer or cervical cancer in situ);\n\n          -  CNS metastasis that is symptomatic and/or requires treatment;\n\n          -  Any condition or illness that, in the opinion of the Investigator or the medical\n             monitor, would compromise patient safety or interfere with the evaluation of the\n             safety of the drug;\n\n          -  Known allergy to treatment medication or its excipients;\n\n          -  Any other medical or psychological condition that would preclude participation in the\n             study or compromise ability to give informed consent. Exclusion criteria for Phase II\n             patients only\n\n          -  Progression on first line therapy;\n\n          -  A complete response on first line therapy;\n\n          -  Use of first line therapy for longer than 4 months;\n\n          -  Use of any first line treatment with a chemotherapy regimen other than FOLFOX,\n             FOLFIRI or CAPOX (each with or without bevacizumab).\n\n          -  More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or\n             irinotecan."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "133", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028442", 
            "org_study_id": "ColoAd1-1001"
        }, 
        "intervention": {
            "arm_group_label": "ColoAd1", 
            "description": "Oncolytic virus", 
            "intervention_name": "ColoAd1", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jean-pascal.machiels@uclouvain.be", 
                    "last_name": "Jean-Pascal Machiels, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "B-1200"
                    }, 
                    "name": "Cliniques Universitaires St Luc"
                }, 
                "investigator": {
                    "last_name": "Jean-Pascal Machiels, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sylvie.rottey@ugent.be", 
                    "last_name": "Sylvie Rottey, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Ghent University Hospital"
                }, 
                "investigator": {
                    "last_name": "Sylvie Rottey, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ramonsalazar@iconcologica.net", 
                    "last_name": "Ramon Salazar, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08970"
                    }, 
                    "name": "Institut Catala d Oncologica"
                }, 
                "investigator": {
                    "last_name": "Ramon Salazar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "emiliano.calvo@start.stoh.com", 
                    "last_name": "Emiliano Calvo, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "START - Hospital Universitario Madrid Sanchinarrio"
                }, 
                "investigator": {
                    "last_name": "Emiliano Calvo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Clinical Study Of ColoAd1 Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "christine.blanc@psioxus.com", 
            "last_name": "Christine Wilkinson-Blanc, MD"
        }, 
        "overall_contact_backup": {
            "email": "john.beadle@psioxus.com", 
            "last_name": "John Beadle, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "- Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of ColoAd1 when administered by sub-acute fractionated IV injection (phase I Dose Escalation) and recommended dose for phase II.", 
            "measure": "Phase 1 - Maximum Tolerated Dose", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 22"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028442"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "PsiOxus Therapeutics Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PsiOxus Therapeutics Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}